These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22444677)

  • 41. Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit.
    Hu E; Tasker A; White RD; Kunz RK; Human J; Chen N; Bürli R; Hungate R; Novak P; Itano A; Zhang X; Yu V; Nguyen Y; Tudor Y; Plant M; Flynn S; Xu Y; Meagher KL; Whittington DA; Ng GY
    J Med Chem; 2008 Jun; 51(11):3065-8. PubMed ID: 18447379
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.
    Wu CH; Hung MS; Song JS; Yeh TK; Chou MC; Chu CM; Jan JJ; Hsieh MT; Tseng SL; Chang CP; Hsieh WP; Lin Y; Yeh YN; Chung WL; Kuo CW; Lin CY; Shy HS; Chao YS; Shia KS
    J Med Chem; 2009 Jul; 52(14):4496-510. PubMed ID: 19530697
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 5-Sulfonyl-benzimidazoles as selective CB2 agonists.
    Verbist BM; De Cleyn MA; Surkyn M; Fraiponts E; Aerssens J; Nijsen MJ; Gijsen HJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2574-9. PubMed ID: 18394887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors.
    Merighi S; Simioni C; Gessi S; Varani K; Borea PA
    Biochem Pharmacol; 2010 Feb; 79(3):471-7. PubMed ID: 19766600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
    Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
    J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis.
    Maekawa T; Nojima H; Kuraishi Y; Aisaka K
    Eur J Pharmacol; 2006 Aug; 542(1-3):179-83. PubMed ID: 16824511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: hit to lead.
    Siu T; Kozina ES; Jung J; Rosenstein C; Mathur A; Altman MD; Chan G; Xu L; Bachman E; Mo JR; Bouthillette M; Rush T; Dinsmore CJ; Marshall CG; Young JR
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7421-5. PubMed ID: 21044843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
    Brogi S; Corelli F; Di Marzo V; Ligresti A; Mugnaini C; Pasquini S; Tafi A
    Eur J Med Chem; 2011 Feb; 46(2):547-55. PubMed ID: 21183257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
    Ohta H; Ishizaka T; Tatsuzuki M; Yoshinaga M; Iida I; Yamaguchi T; Tomishima Y; Futaki N; Toda Y; Saito S
    Bioorg Med Chem; 2008 Feb; 16(3):1111-24. PubMed ID: 18006322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
    Manley PJ; Zartman A; Paone DV; Burgey CS; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT; Trotter BW
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2359-64. PubMed ID: 21420857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies.
    Lavey BJ; Kozlowski JA; Hipkin RW; Gonsiorek W; Lundell DJ; Piwinski JJ; Narula S; Lunn CA
    Bioorg Med Chem Lett; 2005 Feb; 15(3):783-6. PubMed ID: 15664857
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
    Manera C; Benetti V; Castelli MP; Cavallini T; Lazzarotti S; Pibiri F; Saccomanni G; Tuccinardi T; Vannacci A; Martinelli A; Ferrarini PL
    J Med Chem; 2006 Oct; 49(20):5947-57. PubMed ID: 17004710
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors.
    Govaerts SJ; Hermans E; Lambert DM
    Eur J Pharm Sci; 2004 Nov; 23(3):233-43. PubMed ID: 15489124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
    Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
    Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach.
    Meng T; Wang J; Peng H; Fang G; Li M; Xiong B; Xie X; Zhang Y; Wang X; Shen J
    Eur J Med Chem; 2010 Mar; 45(3):1133-9. PubMed ID: 20047779
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
    Durdagi S; Kapou A; Kourouli T; Andreou T; Nikas SP; Nahmias VR; Papahatjis DP; Papadopoulos MG; Mavromoustakos T
    J Med Chem; 2007 Jun; 50(12):2875-85. PubMed ID: 17521177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor.
    Yates AS; Doughty SW; Kendall DA; Kellam B
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3758-62. PubMed ID: 15993070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
    Imada T; Cho N; Imaeda T; Hayase Y; Sasaki S; Kasai S; Harada M; Matsumoto H; Endo S; Suzuki N; Furuya S
    J Med Chem; 2006 Jun; 49(13):3809-25. PubMed ID: 16789738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.
    Lange JH; van der Neut MA; Wals HC; Kuil GD; Borst AJ; Mulder A; den Hartog AP; Zilaout H; Goutier W; van Stuivenberg HH; van Vliet BJ
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1084-9. PubMed ID: 20031412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.
    LaBuda CJ; Koblish M; Little PJ
    Eur J Pharmacol; 2005 Dec; 527(1-3):172-4. PubMed ID: 16316653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.